Defining unacceptable HLA antigens

Current Opinion in Organ Transplantation

Volumn 13, Issue 4, 2008, Pages 405-410

  Zachary, Andrea A ^a   Montgomery, Robert A ^a   Leffell, Mary S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Desensitization; Immunosuppression; Risk

Indexed keywords

HLA A ANTIGEN; HLA ANTIBODY; HLA ANTIGEN; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; HLA DR1 ANTIGEN; IMMUNOGLOBULIN ANTIBODY;

CELL POPULATION; DESENSITIZATION; DONOR SELECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OPTICAL DENSITY; REVIEW; SENSITIZATION;

ANTIBODIES; ANTIBODY SPECIFICITY; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ORGAN TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TRANSPLANTATION TOLERANCE;

EID: 54549090696     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283071450     Document Type: Review

References (46)

1. Ramirez CB, Marino IR. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Therapy 2007; 7:137-148.
2. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006; 81:1361 -1367.
3. Mottershead M, Neuberger J. Daclizumab. Expert Opin Biol Therapy 2007; 7:1583-1596.
4. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6:859-866.
5. Brayman K. New insights into the mechanisms of action of thymoglobulin. Transplantation 2007; 84:S3-S4.
6. Mueller TF. Mechanisms of action of thymoglobulin. Transplantation 2007; 84:S5-S10.
7. Zand MS. Therapeutic antibody agents for B-cell immunomodulation in renal transplantation. Transplantation 2007; 84:S11 -S19.
8. Hirose R, Vincenti F. Immunosupression: today, tomorrow, and withdrawal. Semin Liver Dis 2006; 26:201 -210.
9. Kaplan B. Overcoming barriers to long-term graft survival. Am J Kidney Dis 2006; 47:S52-S64.
10. Zachary AA, Montgomery RA, Jordan SC, et al. 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation. Tissue Antigens 2007; 69:160-173.
11. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70:887-895.
12. Vo AA, Toyoda M, Peng A, et al. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006; 6:2384-2390.
13. Stegall MD, Gloor J, Winters L, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6:346-351.
14. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7:842-846.
15. Kaplan B, Gangemi A, Thielke J, et al. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007; 83:99-100.
16. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: whose problem is it? Front Biosci 2008; 13:1396-1412.
17. Nikaein A, Spiridon C, Hunt J, et al. Pretransplant level of soluble CD30 is associated with infection after heart transplantation. Clin Transplant 2007; 21:744-747.
18. Rodriguez LM, Paris SC, Arbelaez M, et al. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for the graft loss. Hum Immunol 2007; 68:652-660.
19. Giannoli C, Bonnet MC, Perrat G, et al. High pretransplantation soluble CD30 levels: impact in renal transplantation. Transplant Proc 2007; 39:2574-2575.
20. Canossi A, Piazza A, Poggi E, et al. Renal allograft immune response is influenced by patient and donor cytokine genotypes. Transplant Proc 2007; 39:1805-1812.
21. Stastny P, Lavingia B, Fixler DE, et al. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation 2007; 84:738-745.
22. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, Luminex binding antibodies: a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7:2809-2815.
23. Cambell PM, Salam A, Ryan EA, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007; 7:1242-1248.
24. Masson E, Stern M, Chabod J, et al. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies. J Heart Lung Transplant 2007; 26:62-645.
25. Doran TJ, Geczy AF, Painter D, et al. A large, single center investigation of the immunogenetic factors affecting liver transplantation. Transplanation 2000; 69:1491 -1498.
26. Zachary AA, Hart JM, Lucas DP, Leffell MS. The cost of mismatching. In: Terasaki PI, CeckaJM, editors. Clinical transplants. Los Angeles, CA:Terasaki Foundation Laboratory; 2007. pp. 19-27.
27. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical revevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8:324-331.
28. Bielmann D, Honger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7:626-632.
29. Schaub S, Scornik JC. High-tech detection of HLA antibodies and complement: prospects and limitations. Am J Transplant 2008; 8:5-6.
30. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008; 8:41 -49.
31. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7:857-863.
32. Eijsink C, Zoet YM, Kardol MJ, et al. Identification of acceptable HLA mismatches in immunized patients using single-antigen-expressing cell lines. Tissue Antigens 2007; 69:354-357.
33. Lieber SR, Perez FVT, Tabossi MR, et al. Effect of panel-reactive antibody in predicting crossmatch selection of cadaveric kidney recipients. Transplant Proc 2007; 39:429-431.
34. Higgins R, Hathaway M, Lowe D, et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007; 84:875-884.
35. Phelan D, Jendridak M, Surrendra S, et al. Best practices: are they clinically relevant? World Transplant Congress - Transplantation. Am J Transplant 2006; 6 (Suppl 2):69 [abstract 8].
36. Appel JZ, Hartwig MG, Cantu E, et al. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006; 81:1049-1057.
37. Zangwill SD, Ellis TM, Zlotocha J, et al. The virtual crossmatch - a screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant 2006; 10:38-41.
38. Zangwill S, Ellis T, Stendahl G, et al. J. Practical application of the virtual crossmatch. Pediatr Transplant 2007; 11:650-654.
39. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7:1027-1031.
40. Jindra PT, Hsueh A, Hong L, Gjertson D, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol 2008; 180:2214-2224.
41. Singh D, Kiberd BA, West KA, et al. Importance of peak PRA in predicting the kidney transplant survival in highly sensitized patients. Transplant Proc 2003; 35:2395-2397.
42. Baron C, Pastural M, Lang P, et al. Long-term kidney graft survival across a positive historic but negative current sensitized cross-match. Transplantation 2002; 73:232-236.
43. Cardella CJ. The use of the kidney with an historical positive, and current negative crossmatch. Pediatr Nephrol 1991; 5:126-129.
44. Zachary AA, Kopchaliiska D, Montgomery RA, Leffell MS. HLA-specific B cells: I. A method for their detection, quantitation, and isolation using HLA tetramers. Transplantation 2007; 83:982-988.
45. Zachary AA, Kopchaliiska D, Montgomery RA, Leffell MS. HLA-specific B cells: II. Application to transplantation. Transplantation 2007; 83:989-994.
46. Duquesnoy R, Medhat A. HLA matchmaker: a molecularly based algorithm for histocompatibility determination: V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Human Immunol 2007; 68:12-25.